A011040 Stock Overview
Manufactures and sells pharmaceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Kyung Dong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,840.00 |
| 52 Week High | ₩8,280.00 |
| 52 Week Low | ₩5,560.00 |
| Beta | 0.77 |
| 1 Month Change | -6.26% |
| 3 Month Change | -8.75% |
| 1 Year Change | -8.61% |
| 3 Year Change | -45.42% |
| 5 Year Change | -27.81% |
| Change since IPO | 259.51% |
Recent News & Updates
Recent updates
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend
Feb 18
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?
Feb 03Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 19Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?
Dec 20We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05Shareholder Returns
| A011040 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.5% | 0.4% | -0.7% |
| 1Y | -8.6% | 10.0% | -5.5% |
Return vs Industry: A011040 underperformed the KR Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: A011040 underperformed the KR Market which returned -5.5% over the past year.
Price Volatility
| A011040 volatility | |
|---|---|
| A011040 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A011040 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A011040's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | 364 | Deok-Hee Ryu | www.kdpharma.co.kr |
Kyung Dong Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, cardiovascular and dysplidemia, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, antihistamine, CNS, antiobesity, NVP, neuropathic, osteoporosis, respiratory, allergy, and arthrifuge categories. It also provides OTC medicines for pain/inflammation, cardiovascular, hepatic protectors, combined metabolic agents, respiratory, gastrointestinal, calcium agent, vitamins and minerals, antihistamine, antifungal, antibiotic, otorhinolarynglogy agent, anti-inflammatory enzyme, dermatologic, hair solvents, capillary stabilizing agents, antiviral, tonics, and contraceptive categories; and health functional foods, quasi drugs, and APIs.
Kyung Dong Pharmaceutical Co., Ltd. Fundamentals Summary
| A011040 fundamental statistics | |
|---|---|
| Market cap | ₩157.34b |
| Earnings (TTM) | -₩17.00b |
| Revenue (TTM) | ₩189.19b |
0.8x
P/S Ratio-9.3x
P/E RatioIs A011040 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A011040 income statement (TTM) | |
|---|---|
| Revenue | ₩189.19b |
| Cost of Revenue | ₩80.17b |
| Gross Profit | ₩109.02b |
| Other Expenses | ₩126.03b |
| Earnings | -₩17.00b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -631.16 |
| Gross Margin | 57.63% |
| Net Profit Margin | -8.99% |
| Debt/Equity Ratio | 18.3% |
How did A011040 perform over the long term?
See historical performance and comparisonDividends
6.8%
Current Dividend Yield-64%
Payout RatioDoes A011040 pay a reliable dividends?
See A011040 dividend history and benchmarks| Kyung Dong Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 18 2025 |
| Days until Ex dividend | 39 days |
| Days until Dividend pay date | 73 days |
Does A011040 pay a reliable dividends?
See A011040 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 03:51 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kyung Dong Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hong-Sik Jeong | LS Securities Co., Ltd. |
| Tae Gi Ha | SK Securities Co., Ltd. |